Co-Diagnostics CODX

NASDAQ CODX

$1.08 +0.00 (+0.00%)

At close: Oct 2, 2026 · 4:00 PM EDT

Key Stats

Market Cap4.65 Mn

P/E-0.10

P/S6.30

Add ratio to table…

About

Co-Diagnostics, Inc. develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, including molecular tools for detection of infectious diseases. The company’s diagnostics systems enable dependable, low-cost molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. Co-Diagnostics’ technical advance involves a novel, proprietary approach to polymerase chain reaction test design of primer and probe structure that reduces primer-dimer amplification, which adversely interferes with identification of target DNA or RNA.

Co-Diagnostics generates revenue primarily through the sale of its diagnostic reagent kits and related products for the detection of infectious diseases such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. The company sells its tests to qualified clinical laboratories in the United States and internationally, including through its global network of distributors covering more than 50 countries. In addition, Co-Diagnostics may sell diagnostic equipment from other manufacturers, including its Co-Dx Box™, as part of its testing solutions.

The company operates through the following segments:

Infectious Disease Diagnostics: This segment focuses on the design, development, manufacturing and sale of PCR-based diagnostic tests for the detection of infectious diseases. Co-Diagnostics has obtained regulatory clearance in the European Community and India for PCR diagnostic tests targeting COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. In the United States, the company received Emergency Use Authorization for its Logix Smart® COVID-19 detection test, which it sells to qualified labs. The company has also commercialized multiplexed tests for mosquito-borne diseases to support municipal vector control efforts.
Co-Dx PCR Platform: This segment encompasses the development of a portable diagnostic device and test system designed for point-of-care and at-home use. The system includes the Co-Dx™ PCR Pro® instrument and a mobile application, collectively referred to as the Co-Dx™ PCR platform. Co-Diagnostics completed its first FDA 510(k) submission in June 2024 for the Co-Dx PCR Pro instrument, the Co-Dx PCR COVID-19 Test, and the Co-Dx PCR mobile app for over-the-counter use, though the submission was voluntarily withdrawn following discussions with the FDA. The company is now focusing development efforts on the Co-Dx PCR Flu A/B, COVID-19, RSV multiplex test (ABCR), with clinical performance studies currently underway.

Co-Diagnostics holds a competitive position in the molecular diagnostics industry through its proprietary Co-Primers® technology, which improves test specificity by reducing false positives from primer-dimer formation. This technology enables the company to design highly specific multiplex PCR tests for multiple targets, single nucleotide polymorphism detection, and next-generation sequencing applications. By owning its proprietary platform, Co-Diagnostics avoids patent royalties that competitors must pay, allowing it to offer lower-cost diagnostic tests while maintaining profit margins. The company’s intellectual property is protected by more than 20 granted or pending U. S. and foreign patents, as well as trade secrets and copyrights.

Co-Diagnostics serves clinical laboratories, hospitals, and public health organizations in the United States and internationally. The company has distributed its Logix Smart® COVID-19 test and other diagnostic products to clinical labs in more than 50 countries through its global distributor network. Its tests have been cleared for sale in countries such as the United Kingdom, Australia, India, and Mexico by local regulatory bodies. Additionally, Co-Diagnostics collaborates with customers to develop custom tests for genetic trait detection in plant and animal genomes, supporting agricultural and veterinary applications.

Investment Thesis

▲ Bull case

Co-Diagnostics is strategically leveraging its CoSara joint venture in India to unlock a substantial addressable market opportunity that the market is significantly underestimating, with the recent expansion into Bangladesh, Pakistan, Nepal and Sri Lanka increasing the total addressable market to approximately $13 billion. This expansion is not merely geographic but represents a structural shift in the company's commercialization pathway, as CoSara has matured into a self-sustaining entity with established manufacturing capabilities, a nationwide distribution network serving hundreds of laboratory customers, and 15 PCR tests already cleared through India's CDSCO regulatory pathway. The recent receipt of the CDSCO license to manufacture the PCR Pro instrument locally in India marks a critical inflection point that enables end-to-end control over production, reduces dependency on Utah-based manufacturing, and positions the joint venture for accelerated commercialization of its tuberculosis test, which aligns with updated WHO guidelines recommending near point-of-care molecular tests and tongue swab sampling—a development that directly leverages Co-Diagnostics' platform design supported by prior Gates Foundation-funded work. The company's expectation to achieve commercialization of the TB test in India by Q3 FY26, supported by the high prevalence of latent TB in the population ensuring rapid clinical sample accrual, represents a near-term catalyst that could initiate meaningful revenue generation from a market where diagnostic demand is both structurally growing and underserved, yet this timeline and its implications for CoSara's potential path to becoming a standalone public entity via a SPAC transaction are not being priced into the current valuation, which remains fixated on the company's historical grant-dependent revenue model and near-term losses.
The advancement of Co-Diagnostics' Ebola PCR development program through its CoSara joint venture represents a hidden catalyst with significant asymmetric upside potential that the market is overlooking due to its classification as early-stage R&D, despite the dual-assay strategy (pan-Ebola detection and species-specific multiplexing) being uniquely positioned to address critical gaps in outbreak response infrastructure in Central Africa. The development of a blood-based pathogen assay for the Co-Dx PCR Pro platform would represent a fundamental expansion of the platform's utility beyond respiratory and tuberculosis applications into high-value, high-margin diagnostic segments such as hemorrhagic fever monitoring, where rapid molecular detection is currently limited and often reliant on centralized laboratories with delayed turnaround times. This capability aligns with the company's stated goal of making molecular diagnostics more accessible in both developed and emerging markets through decentralized, point-of-care testing, and the fact that this work is being conducted within the established CoSara infrastructure—which already possesses regulatory experience, manufacturing readiness, and distribution networks across South Asia—lowers the incremental cost and time to deploy such assays should outbreaks emerge. The market is failing to appreciate how this initiative transforms the Co-Dx platform from a collection of single-disease tests into a resilient, adaptable diagnostic ecosystem capable of rapid response to emerging threats, a characteristic that could drive future government and NGO partnerships, grant funding, and stockpiling agreements—revenue streams that are non-dilutive, scalable, and structurally tied to the company's core IP, yet remain absent from current financial models that focus narrowly on near-term product sales in the U.S. respiratory market.
Co-Diagnostics' AI-driven capabilities, particularly the Co-Dx primer AI platform, constitute a significantly underappreciated long-term value driver that is being treated as a peripheral innovation rather than a core competitive moat, despite its direct integration into assay design, result interpretation, and system performance enhancement across the entire Co-Dx PCR platform. The company has already deployed multiple AI models in production with ongoing development, and the platform's ability to unify diagnostics, data analytics, and operational efficiency creates a feedback loop where each deployed test generates data that improves future assay design—a self-reinforcing cycle that reduces R&D cycle times, lowers failure rates in clinical validation, and enables rapid adaptation to evolving pathogens, as demonstrated in the swift pivot from a four-plex to a three-plex upper respiratory test based on real-time epidemiological trends. This AI infrastructure is especially valuable in the context of the company's international expansion strategy, where localized manufacturing through CoSara and CoMira requires adaptive assay configuration to account for regional pathogen strains and regulatory requirements; the AI platform enables this agility without necessitating costly, time-consuming re-engineering of core chemistry. The market is undervaluing this capability because it does not yet appear as a line-item revenue stream, yet it functions as a force multiplier that enhances the success probability and speed to market of all other growth pillars—TB, HPV, upper respiratory, and Ebola—while simultaneously reducing the capital intensity of innovation, a structural advantage that becomes increasingly critical as the company scales globally and faces pressure to maintain technological leadership against larger diagnostics competitors with greater R&D budgets.

Co-Diagnostics is strategically leveraging its CoSara joint venture in India to unlock a substantial addressable market opportunity that the market is significantly underestimating, with the recent expansion into Bangladesh, Pakistan, Nepal and Sri Lanka increasing the total addressable market to approximately $13 billion. This expansion is not merely geographic but represents a structural shift in the company's commercialization pathway, as CoSara has matured into a self-sustaining entity with established manufacturing capabilities, a nationwide distribution network serving hundreds of laboratory customers, and 15 PCR tests already cleared through India's CDSCO regulatory pathway. The recent receipt of the CDSCO license to manufacture the PCR Pro instrument locally in India marks a critical inflection point that enables end-to-end control over production, reduces dependency on Utah-based manufacturing, and positions the joint venture for accelerated commercialization of its tuberculosis test, which aligns with updated WHO guidelines recommending near point-of-care molecular tests and tongue swab sampling—a development that directly leverages Co-Diagnostics' platform design supported by prior Gates Foundation-funded work. The company's expectation to achieve commercialization of the TB test in India by Q3 FY26, supported by the high prevalence of latent TB in the population ensuring rapid clinical sample accrual, represents a near-term catalyst that could initiate meaningful revenue generation from a market where diagnostic demand is both structurally growing and underserved, yet this timeline and its implications for CoSara's potential path to becoming a standalone public entity via a SPAC transaction are not being priced into the current valuation, which remains fixated on the company's historical grant-dependent revenue model and near-term losses.
The advancement of Co-Diagnostics' Ebola PCR development program through its CoSara joint venture represents a hidden catalyst with significant asymmetric upside potential that the market is overlooking due to its classification as early-stage R&D, despite the dual-assay strategy (pan-Ebola detection and species-specific multiplexing) being uniquely positioned to address critical gaps in outbreak response infrastructure in Central Africa. The development of a blood-based pathogen assay for the Co-Dx PCR Pro platform would represent a fundamental expansion of the platform's utility beyond respiratory and tuberculosis applications into high-value, high-margin diagnostic segments such as hemorrhagic fever monitoring, where rapid molecular detection is currently limited and often reliant on centralized laboratories with delayed turnaround times. This capability aligns with the company's stated goal of making molecular diagnostics more accessible in both developed and emerging markets through decentralized, point-of-care testing, and the fact that this work is being conducted within the established CoSara infrastructure—which already possesses regulatory experience, manufacturing readiness, and distribution networks across South Asia—lowers the incremental cost and time to deploy such assays should outbreaks emerge. The market is failing to appreciate how this initiative transforms the Co-Dx platform from a collection of single-disease tests into a resilient, adaptable diagnostic ecosystem capable of rapid response to emerging threats, a characteristic that could drive future government and NGO partnerships, grant funding, and stockpiling agreements—revenue streams that are non-dilutive, scalable, and structurally tied to the company's core IP, yet remain absent from current financial models that focus narrowly on near-term product sales in the U.S. respiratory market.
Co-Diagnostics' AI-driven capabilities, particularly the Co-Dx primer AI platform, constitute a significantly underappreciated long-term value driver that is being treated as a peripheral innovation rather than a core competitive moat, despite its direct integration into assay design, result interpretation, and system performance enhancement across the entire Co-Dx PCR platform. The company has already deployed multiple AI models in production with ongoing development, and the platform's ability to unify diagnostics, data analytics, and operational efficiency creates a feedback loop where each deployed test generates data that improves future assay design—a self-reinforcing cycle that reduces R&D cycle times, lowers failure rates in clinical validation, and enables rapid adaptation to evolving pathogens, as demonstrated in the swift pivot from a four-plex to a three-plex upper respiratory test based on real-time epidemiological trends. This AI infrastructure is especially valuable in the context of the company's international expansion strategy, where localized manufacturing through CoSara and CoMira requires adaptive assay configuration to account for regional pathogen strains and regulatory requirements; the AI platform enables this agility without necessitating costly, time-consuming re-engineering of core chemistry. The market is undervaluing this capability because it does not yet appear as a line-item revenue stream, yet it functions as a force multiplier that enhances the success probability and speed to market of all other growth pillars—TB, HPV, upper respiratory, and Ebola—while simultaneously reducing the capital intensity of innovation, a structural advantage that becomes increasingly critical as the company scales globally and faces pressure to maintain technological leadership against larger diagnostics competitors with greater R&D budgets.

▼ Bear case

Co-Diagnostics continues to face fundamental challenges in achieving sustainable commercial revenue generation, as evidenced by the steep year-over-year decline in total revenue to $0.6 million in FY25 from $3.9 million in FY24, a trend driven not only by the non-recognition of prior grant funding but also by persistently weak product sales, which fell to $0.4 million from $0.8 million despite the company's repeated emphasis on advancing toward commercialization. The firm remains heavily dependent on non-dilutive funding sources such as grants and equity offerings—net cash provided by financing activities was $11.7 million in FY25, largely from ATM programs and registered direct offerings—indicating an inability to self-fund operations through product revenue, a dependency that is exacerbated by the $18.9 million noncash impairment charge on in-process R&D intangibles, which signals that significant portions of its development pipeline may not achieve the commercial viability previously anticipated. While management highlights cost discipline through reduced operating expenses ex-impairment, the underlying business model has yet to demonstrate traction in any major market, with the U.S. FDA submission for the upper respiratory test still pending and no clear timeline for meaningful U.S. commercialization beyond the India-focused TB initiative, leaving the company vulnerable to continued cash burn without a visible path to profitability.
The company's international expansion strategy, particularly the CoSara and CoMira joint ventures, carries significant execution and structural risks that are being downplayed in management's optimistic narrative, including regulatory uncertainty in emerging markets, dependency on local partners for manufacturing and distribution, and the unproven nature of pursuing a SPAC transaction for CoSara as a viable path to value creation. Although CoSara has obtained the CDSCO license to manufacture the PCR Pro instrument in India, the transition from technology transfer to scalable, compliant local production remains untested at scale, and any delays in setting up the oligonucleotide lab or training personnel could push back the anticipated Q3 FY26 commercialization timeline for the TB test, especially given that the clinical trial's success hinges on not just sample availability but also successful analytical validation and regulatory review—processes that are inherently unpredictable in emerging regulatory environments. Furthermore, while the joint venture model reduces upfront capital requirements, it also dilutes Co-Diagnostics' control over commercial decisions, profit sharing, and IP enforcement in key markets like India and Saudi Arabia, where local partners may prioritize regional interests over global platform integration, and the lack of disclosed financial terms or ownership structures in these JVs obscures the true economic benefit to Co-Diagnostics shareholders, making the touted $13 billion addressable market expansion potentially misleading if the company captures only a small fraction of the value through royalties or equity stakes.
Co-Diagnostics' reliance on emerging infectious disease opportunities, such as the Ebola PCR assay development, represents a speculative and inherently unstable growth driver that the market may be ignoring due to its episodic nature, lack of predictable demand, and high failure rate in regulatory and commercialization pathways. The development of blood-based assays for pathogens like Ebola, while scientifically plausible, faces substantial hurdles including the need for biosafety level (BSL) compliance in manufacturing and handling, limited access to clinical samples during inter-outbreak periods, and the requirement for stringent regulatory validation that can take years—factors that are not adequately addressed in the company's forward-looking statements, which emphasize rapid response capabilities without detailing the infrastructural, financial, or regulatory investments needed to sustain readiness between outbreaks. Moreover, the platform's expansion into blood-based testing would require significant re-engineering of sample preparation protocols, potential changes to the PCR Pro device's fluidics, and new validation studies, contradicting management's implication that adding such capabilities is a simple "lighting up" of existing chemistry; the assertion that no redesign would be needed for adding back COVID to the upper respiratory test was already met with skepticism regarding FDA requirements, and extending this logic to entirely new sample types like whole blood ignores the fundamental differences in matrix effects, inhibitors, and extraction complexity that could necessitate substantial assay re-optimization. This pursuit diverts focus and capital from more immediate, addressable markets like respiratory and TB diagnostics, where the company has already made tangible progress, and instead bets on low-probability, high-impact events that may never materialize into sustainable revenue, leaving investors exposed to prolonged losses without a clear, near-term inflection point.

Co-Diagnostics continues to face fundamental challenges in achieving sustainable commercial revenue generation, as evidenced by the steep year-over-year decline in total revenue to $0.6 million in FY25 from $3.9 million in FY24, a trend driven not only by the non-recognition of prior grant funding but also by persistently weak product sales, which fell to $0.4 million from $0.8 million despite the company's repeated emphasis on advancing toward commercialization. The firm remains heavily dependent on non-dilutive funding sources such as grants and equity offerings—net cash provided by financing activities was $11.7 million in FY25, largely from ATM programs and registered direct offerings—indicating an inability to self-fund operations through product revenue, a dependency that is exacerbated by the $18.9 million noncash impairment charge on in-process R&D intangibles, which signals that significant portions of its development pipeline may not achieve the commercial viability previously anticipated. While management highlights cost discipline through reduced operating expenses ex-impairment, the underlying business model has yet to demonstrate traction in any major market, with the U.S. FDA submission for the upper respiratory test still pending and no clear timeline for meaningful U.S. commercialization beyond the India-focused TB initiative, leaving the company vulnerable to continued cash burn without a visible path to profitability.
The company's international expansion strategy, particularly the CoSara and CoMira joint ventures, carries significant execution and structural risks that are being downplayed in management's optimistic narrative, including regulatory uncertainty in emerging markets, dependency on local partners for manufacturing and distribution, and the unproven nature of pursuing a SPAC transaction for CoSara as a viable path to value creation. Although CoSara has obtained the CDSCO license to manufacture the PCR Pro instrument in India, the transition from technology transfer to scalable, compliant local production remains untested at scale, and any delays in setting up the oligonucleotide lab or training personnel could push back the anticipated Q3 FY26 commercialization timeline for the TB test, especially given that the clinical trial's success hinges on not just sample availability but also successful analytical validation and regulatory review—processes that are inherently unpredictable in emerging regulatory environments. Furthermore, while the joint venture model reduces upfront capital requirements, it also dilutes Co-Diagnostics' control over commercial decisions, profit sharing, and IP enforcement in key markets like India and Saudi Arabia, where local partners may prioritize regional interests over global platform integration, and the lack of disclosed financial terms or ownership structures in these JVs obscures the true economic benefit to Co-Diagnostics shareholders, making the touted $13 billion addressable market expansion potentially misleading if the company captures only a small fraction of the value through royalties or equity stakes.
Co-Diagnostics' reliance on emerging infectious disease opportunities, such as the Ebola PCR assay development, represents a speculative and inherently unstable growth driver that the market may be ignoring due to its episodic nature, lack of predictable demand, and high failure rate in regulatory and commercialization pathways. The development of blood-based assays for pathogens like Ebola, while scientifically plausible, faces substantial hurdles including the need for biosafety level (BSL) compliance in manufacturing and handling, limited access to clinical samples during inter-outbreak periods, and the requirement for stringent regulatory validation that can take years—factors that are not adequately addressed in the company's forward-looking statements, which emphasize rapid response capabilities without detailing the infrastructural, financial, or regulatory investments needed to sustain readiness between outbreaks. Moreover, the platform's expansion into blood-based testing would require significant re-engineering of sample preparation protocols, potential changes to the PCR Pro device's fluidics, and new validation studies, contradicting management's implication that adding such capabilities is a simple "lighting up" of existing chemistry; the assertion that no redesign would be needed for adding back COVID to the upper respiratory test was already met with skepticism regarding FDA requirements, and extending this logic to entirely new sample types like whole blood ignores the fundamental differences in matrix effects, inhibitors, and extraction complexity that could necessitate substantial assay re-optimization. This pursuit diverts focus and capital from more immediate, addressable markets like respiratory and TB diagnostics, where the company has already made tangible progress, and instead bets on low-probability, high-impact events that may never materialize into sustainable revenue, leaving investors exposed to prolonged losses without a clear, near-term inflection point.

Geographical Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Diagnostic Equipment

View all peers

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	241.25 Bn	34.75	5.21	42.55 Bn
2	ABT	Abbott Laboratories	167.33 Bn	31.02	3.59	32.61 Bn
3	DHR	Danaher Corp /De/	148.83 Bn	37.30	5.93	26.56 Bn
4	ISRG	Intuitive Surgical Inc	142.00 Bn	45.27	12.87	-
5	MDT	Medtronic plc	110.70 Bn	21.16	2.95	28.15 Bn
6	SYK	Stryker Corp	104.72 Bn	28.08	4.05	14.94 Bn
7	BSX	Boston Scientific Corp	62.66 Bn	17.30	2.98	12.62 Bn
8	CODX	Co-Diagnostics, Inc.	0.00 Bn	-0.10	6.30	-

Co-Diagnostics CODX

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password